Stonebridge Capital Advisors’s DexCom DXCM Stock Holding History

Stonebridge Capital Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-36	Closed	-$5K	–	1035
2021 Q4	$5K	Buy	+36	New	+$5.17K	﹤0.01%	731

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Stonebridge Capital Advisors's DXCM Position: Q1 2022 in Review

Stonebridge Capital Advisors sold out of DexCom (DXCM) in Q1 2022, closing a stake of 36 shares — an estimated $5K sold.

Stonebridge Capital Advisors first reported a position in DXCM in Q4 2021 and held it in 1 quarter. The position peaked at $5K in Q4 2021. 861 funds tracked by Wall St. Rank hold DXCM as of Q1 2022.

Stonebridge Capital Advisors reported no remaining DexCom position as of Q1 2022 after selling out during the quarter.
Stonebridge Capital Advisors sold 36 DexCom shares in Q1 2022, an estimated $5K.
Stonebridge Capital Advisors first reported a position in DexCom in Q4 2021 and held it in 1 quarter.
Stonebridge Capital Advisors's DexCom position peaked at $5K in Q4 2021.
861 funds tracked by Wall St. Rank held DexCom as of Q1 2022.

Based on Stonebridge Capital Advisors's 13F filing for Q1 2022, filed 12 May 2022.